您的账号已在其他设备登录,您当前账号已强迫下线,
如非您本人操作,建议您在会员中心进行密码修改

确定

晚期非小细胞肺癌抗血管生成药物治疗中国专家共识(2020版)

Chinese expert consensus on antiangiogenic drugs for advanced non-small cell lung cancer (2020 Edition)

摘要:

非小细胞肺癌(NSCLC)是肺癌中最常见的组织学类型,在肺癌中占比超过80%,以铂类为基础的双药化疗方案是治疗晚期NSCLC的传统标准方案,但患者的5年生存率依然很低,不足5%。新生血管的生成在多种实体肿瘤的生长、增殖和转移中发挥着关键作用。抗血管生成药物可作用于肿瘤微环境,使现有肿瘤血管退化,同时抑制肿瘤新生血管生成。随着我国抗血管生成药物的不断发展和药物可及性的不断提高,抗血管生成药物成为晚期NSCLC患者不可或缺的治疗手段之一。共识在《晚期非小细胞肺癌抗血管生成药物治疗中国专家共识(2019年版)》的基础上,由共识编写组根据近一年来发表的临床研究证据,并结合临床实践,整理而成共识更新版,以指导我国肺癌治疗相关的临床科室合理使用抗血管生成药物,进一步提高我国肺癌规范化诊疗水平。

更多
abstracts:

Non-small cell lung cancer (NSCLC) is the most common histological type of lung cancer, accounting for more than 80% of primary lung cancer. Platinum-based chemotherapy is the traditional standard for the treatment of advanced NSCLC, but the 5-years survival rate is still very low, less than 5%. Angiogenesis plays an important role in the growth, proliferation and metastasis of solid tumors. Angiogenesis inhibitors affect the tumor microenvironment, degenerate existing tumor blood vessels and inhibit tumor angiogenesis. Angiogenesis inhibitors are now one of the indispensable treatments for patients with advanced NSCLC through continuous development of new angiogenesis inhibitor and improvement of drug accessibility. This consensus is based on the "Expert consensus on anti-angiogenic drug therapy for advanced non-small cell lung cancer in China (2019 Edition)" , combines with clinical research evidence published in the past years and clinical experience. The consensus-writing group compiles a consensus of guiding clinical departments related to lung cancer treatment to use anti-angiogenic drugs in a standardized manner, and further improves the level of standardized diagnosis and treatment of lung cancer.

More
作者: 中国临床肿瘤学会血管靶向治疗专家委员会 中国临床肿瘤学会非小细胞肺癌专家委员会 中国临床肿瘤学会非小细胞肺癌抗血管生成药物治疗专家组
期刊: 《中华肿瘤杂志》2020年42卷12期 1063-1077页 MEDLINEISTICPKUCSCDCABP
栏目名称: 指南与规范
DOI: 10.3760/cma.j.cn112152-20200918-00836
发布时间: 2021-01-11
  • 浏览:15
  • 下载:34

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!